SG/PUT/ASTRAZENECA/7000/0.1/21.03.25 | Market Closed - Bid/Ask 07:13:37 24/06/2024 BST | Pre-market 06:50:02 | |||
| 0.023 EUR | -4.17% |
|
0.038 | +65.22% |
| Current month | -50.00% | ||
| 1 month | -20.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 0.023 | -4.17% |
| 21/06/24 | 0.024 | -35.14% |
| 20/06/24 | 0.037 | -7.50% |
| 19/06/24 | 0.04 | +90.48% |
| 18/06/24 | 0.021 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 07:13 am
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU7960 |
| ISIN | DE000SU79605 |
| Date issued | 13/02/2024 |
| Strike | 7,000 p |
| Maturity | 21/03/2025 (270 Days) |
| Parity | 10 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.2 € |
|---|---|
| Lowest since issue | 0.019 € |
| Spread | 0.028 € |
| Spread % | 52.83% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.4
USD
Average target price
174.4
USD
Spread / Average Target
+10.15%
- Stock Market
- Warrants
- Warrant
